Table 3.
Safety profile
| Agent | AMG701 (69) | CC-93269 (75) | PF-06863135 (76) | REGN5458 (73) | JNJ-64007957 (teclistamab) (72) | TNB-383B (70) | JNJ-64407564 (talquetamab) (74) | BFCR4350A (cevostamab) (71) |
|---|---|---|---|---|---|---|---|---|
| Target | BCMA | BCMA | BCMA | BCMA | BCMA | BCMA | GPRC5D | FcRH5 |
| Patients (N) | 65 | 19 | 30 | 49 | 149 (84 i.v., 65 s.c.) | 58 | 157 (102 i.v., 55 s.c.) | 53 |
| CRS (grade ≥3) | 65% (9%) | 90% (5%) | 73.3% (0%) | 39% (0%) | 55% (0%) | 45% (0%) | 54% (3%) | 76% (2%) |
| Infection (grade ≥3) | (17%) | NR (26%) | NR (30%) | 47% (18%) | 52% (15%) | 21% (14%) | 38% (8%) | NR |
| Anemia (grade ≥3) | 42% | NR (42%) | 20% (16.7%) | 37% (22%) | 55% (32%) | 21% (17%) | 48% (27%) | 28% (19%) |
| Neutropenia (grade ≥3) | 25% | NR (53%) | 33.3% (26.7%) | 16% (14%) | 57% (46%) | 19% (16%) | 47% (31%) | 17% (15%) |
| Lymphopenia (grade ≥3) | NR | NR | 16% (16%) | 18% (12%) | NR | NR | 40% (36%) | 15% (15%) |
| Thrombocytopenia (grade ≥3) | 21% | NR (21%) | 8% (5%) | 18% (6%) | 40% (22%) | 17% (14%) | 32% (13%) | 32% (25%) |
| Neurotoxicity (grade ≥3) | NR | NR | 20% | 12% (0%) | 5% (1%) | NR | 6% (2%) | 28% (0%) |
| Other common SE (grade ≥3) | Diarrhea 31%, hypophosphatemia 31% | NR | NR | Fatigue 35% (6%), nausea 31% (0%), pyrexia 31% (2%), back pain 27% (4%) | Pyrexia 30% (0%), diarrhea 23% (1%), nausea 22% (1%), fatigue 22% (1%), headache 22% (0%), cough 21% (2%) | Fatigue 24% (2%), headache 22% (2%), nausea 21% (0%) | Skin-related disorder 45%, dysgeusia 38%, fatigue 29% (1%), headache 27% (1%), pyrexia 27% (1%), diarrhea 25% (3%), nail disorders 17% | Hypomagnesemia 28% (0%), diarrhea 28% (2%), hypokalemia 21% (4%) |
Abbreviations: i.v., intravenous; NR, not reported; s.c., subcutaneous; SE, side effect.